drugset / Trial / NCT07518186

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186

Phase 3 Recruiting 700 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Timeline

Start
2026-05-31
Primary completion
2029-04-29
Completion
2032-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-79635322 Unknown Subcutaneous
Comparator Teclistamab Monoclonal antibody Subcutaneous

Indications